ADC Therapeutics Stock Climbs on Promising LOTIS-7 Trial Results

LiquidityWizard · 2025-12-26T05:06:34+00:00

ADC Therapeutics' shares rose 8.49% following positive LOTIS-7 trial results for ZYNLONTA combined with COLUMVI in treating relapsed lymphoma, achieving a 93.3% response rate, signaling significant progress in challenging treatments.

LiquidityWizard

2025-12-26 05:06:34

Abstract generation in progress

ADC Therapeutics (ADCT) shares surged 8.49% to close at $4.60 on Tuesday, riding the wave of encouraging clinical trial data. The biotech company is gearing up for a conference call this morning at 8:00 a.m. EST to discuss the latest developments from its LOTIS-7 trial.

The LOTIS-7 represents a Phase 1b open-label study examining how well ZYNLONTA—ADC Therapeutics’ proprietary antibody-drug conjugate—performs when paired with COLUMVI, Roche’s cancer therapeutic, in treating patients with relapsed or refractory diffuse large B-cell lymphoma. The trial protocol also incorporates two additional combination arms: ZYNLONTA with polatuzumab vedotin and ZYNLONTA with mosunetuzumab.

Clinical Efficacy Data Signals Progress

Results unveiled at the European Hematology Association 2025 Congress this June demonstrate the potential of the combination approach. Among 30 patients evaluated for efficacy, the ZYNLONTA and COLUMVI combination delivered a 93.3% overall response rate, with 86.7% achieving complete response—metrics that underscore the promise of this ADC meta treatment strategy for difficult-to-treat lymphoma cases.

These efficacy figures are noteworthy in the context of ADC Therapeutics’ broader mission to develop antibody-drug conjugates that can address challenging hematologic malignancies where treatment options remain limited.

The views expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.